Difference between revisions of "Hoffmann M, et al, Cell (2020), cited as Ref 13 in DOI: 10.1007/s11886-020-01293-2 (Q11007)"
Jump to navigation
Jump to search
(Created claim: Fifth Author string (P153): Herrler T, #quickstatements; #temporary_batch_1592835784350) |
(Created claim: Sixth Author string (P154): Erichsen S, #quickstatements; #temporary_batch_1592835855539) |
||
| Property / Sixth Author string | |||
| + | Erichsen S | ||
| Property / Sixth Author string: Erichsen S / rank | |||
| + | Normal rank | ||
Revision as of 14:24, 22 June 2020
Cited in: "Cardiovascular Risks in Patients with COVID-19: Potential Mechanisms and Areas of Uncertainty" Curr Cardiol Rep; 2020 04 29 ; 22 (5) 34.
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Hoffmann M, et al, Cell (2020), cited as Ref 13 in DOI: 10.1007/s11886-020-01293-2
|
Cited in: "Cardiovascular Risks in Patients with COVID-19: Potential Mechanisms and Areas of Uncertainty" Curr Cardiol Rep; 2020 04 29 ; 22 (5) 34.
|
Statements
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. In vitro study demonstrating critical roles of ACE2 MPRSS2 in SARS-CoV-2 cell entry. (English)
0 references
2020
0 references
Hoffmann M
0 references
Kleine-Weber H
0 references
Schroeder S
0 references
Kruger N
0 references
Herrler T
0 references
Erichsen S
0 references
